SCIENTIFIC AND BUSINESS PARTNERS
FUJIFILM Cellular Dynamics, Inc. (FCDI) is a leading developer and manufacturer of human induced pluripotent stem cells (hiPSCs) utilized in drug discovery and cell therapies. FCDI offers life science research tools including the company’s inventoried iCell® products that are available in many cell types and sourced from multiple cell lines which can be applied for target identification as well as toxicity testing. The company also offers custom cell development services and integrated drug discovery services with partners. FCDI’s goal is to leverage the vast utility of hiPSCs to advance human health and improve the quality of life for patients around the world.
Founded in 2015 as a spin-out from the Paul Scherrer Institute (ETH), leadXpro is located in Switzerland, between the pharma and science hubs of Basel and Zürich. leadXpro is revolutionising drug discovery for membrane proteins, targeting GPCRs, ion channels and transporters. These proteins represent more than half of clinically-used current drug targets, but remain the most difficult targets for structure-based drug design, due to the challenges in solving their atomic structures in complex with drug candidates.
leadXpro combines state-of-the-art methods for membrane protein science, advanced biophysical methods to characterize drug candidate interactions and pioneering technologies in structural biology, including cryo-EM and time-resolved X-ray crystallography at SwissFEL.
Neuro-Zone S.r.l. is an innovation driven cell-based service company supporting drug discovery, drug repurposing and research projects in the fields of inflammation and age-related pathologies. Neuro-Zone aims to unveil the role of the microenvironment in complex disease scenarios through unique proprietary technological solutions, with the goal of easing lead efficacy assessment. Neuro-Zone activities enable collection of rapid and informative data on efficacy, toxicity, metabolism and mechanism of action. Moreover, they enable effective selection and ranking of the most promising candidates per indication.
Symeres is a leading European contract research organization for drug discovery and development projects. Their services span from early-stage hit finding all the way to the delivery of Phase II API and customised in vitro and in vivo ADME-Tox packages.
The partnership between Symeres and Axxam gives our clients access to best-in-class fully integrated drug discovery services, supported by a culture of scientific excellence, innovation and creativity.
ZoBio offers an integrated fragment-based drug discovery engine based on orthogonal technologies and 16 years of experience. Located in the Netherlands, ZoBio delivers the right small molecule for your target by combining its expertise in protein sciences, biophysical and biochemical assays, structural biology and medicinal chemistry.
Axxam has several research programs in collaboration with a growing network of scientific partners, including several charities, to run state-of-the-art discovery programs and to develop novel technologies that improve the efficiency of the discovery process.
Axxam is a member of the following associations:
Italian Association for the Development of Biotechnology (Assobiotec/Federchimica)
Association of Industries (Assolombarda/Confindustria Milano Monza Brianza)
Lombardy Life Sciences Cluster Association
Society for Laboratory Automation and Screening (SLAS)